Based on the bioinformatics analysis of a large number of glioma specimens, we found that PART1 and hsa-miRNA-429 could regulate SHCBP1 expression and that SHCBP1 can be used as a molecular biomarker to judge the prognosis of glioma patients. Here, PART1 is linked to central nervous system cancer.